Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Leiomyosarcoma × dinutuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 25 Ganglioneuroblastoma 6 Osteosarcoma 4 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Neoplasms 1 Neoplasm, Residual 1 Medulloblastoma 1 Leiomyosarcoma 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1 Bone Neoplasms 1

Interventions

Doxorubicin 22 Gemcitabine 15 Trabectedin 11 Ifosfamide 11 Radiotherapy 10 Docetaxel 10 Dacarbazine 8 pazopanib 6 Temozolomide 4 Specimen Handling 4 Nivolumab 4 Sunitinib 3 Sorafenib 3 Filgrastim 3 Biopsy 3 pembrolizumab 2 pegfilgrastim 2 liposomal doxorubicin 2 eribulin 2 cixutumumab 2 cemiplimab 2 brostallicin 2 belinostat 2 avelumab 2 X-Rays 2 Surgical Procedures, Operative 2 Radiotherapy, Conformal 2 Radiation Dose Hypofractionation 2 Radiation 2 PTC596 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05080790 2025-08-17

DiTuSarc

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡